Limited Benefit of Pembrolizumab Monotherapy in Metastatic TNBC
Metastatic triple-negative breast cancer (TNBC) is associated with a median overall survival of 17.5 months for first-line chemotherapy and 12 months for subsequent courses of treatment, with an objective response rate of 23% and 31% to 34%, respectively. With such poor outcomes, there is a need for metastatic TNBC treatment that can enhance response and prolong survival. Read more.

Increased Risk of Cardiovascular Disease in Older Female BC Survivors
As treatments for breast cancer (BC) become more effective in prolonging survival, there is a greater chance that older women will die of other diseases, most commonly, heart disease. Pharmacists caring for older women with BC, therefore, should be cognizant of the increased risk of cardiovascular disease in this population and to monitor older women, especially those on cardiotoxic medications. Read more.

Do Women Who Switch to Letrozole Maintain Estrogen Suppression?
In 2018, the American Society of Clinical Oncology updated its guidelines to recommend that women with node-positive breast cancer receive extended endocrine therapy for up to 10 years of adjuvant endocrine treatment (ET) to prevent recurrence. Pharmacists who counsel on the utilization of ET, however, should be aware of the limitations of laboratory testing for guiding drug therapy. Read more.